/ database / Nootropic Peptide

Dihexa

Also: PNB-0408

Orally active synaptogenic compound — promising preclinical cognition data.

Evidence
anecdotal
Legal status
research only
Half-life
Unclear in humans
Routes
oral
US-sourcedHPLC testedLot-traceableView this lot's COA →
What it is

Dihexa was developed at Washington State University as a small, orally active angiotensin IV analog that drives new synapse formation via HGF/c-Met signaling. Preclinical cognitive enhancement in rats was dramatic.

Mechanism

Small angiotensin IV analog that activates HGF/c-Met to drive synaptogenesis.

Outcomes it's matched to
Safety

Theoretical concerns around uncontrolled growth (HGF signaling).

  • Active malignancy
  • Pregnancy
Legal context

Research use only. No human safety data.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →